275 related articles for article (PubMed ID: 33472061)
1. Impact of WIN site inhibitor on the WDR5 interactome.
Guarnaccia AD; Rose KL; Wang J; Zhao B; Popay TM; Wang CE; Guerrazzi K; Hill S; Woodley CM; Hansen TJ; Lorey SL; Shaw JG; Payne WG; Weissmiller AM; Olejniczak ET; Fesik SW; Liu Q; Tansey WP
Cell Rep; 2021 Jan; 34(3):108636. PubMed ID: 33472061
[TBL] [Abstract][Full Text] [Related]
2. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
[TBL] [Abstract][Full Text] [Related]
3. WIN site inhibition disrupts a subset of WDR5 function.
Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
[TBL] [Abstract][Full Text] [Related]
4. WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
[TBL] [Abstract][Full Text] [Related]
5. Mitotic gene regulation by the N-MYC-WDR5-PDPK1 nexus.
Streeter SA; Williams AG; Evans JR; Wang J; Guarnaccia AD; Florian AC; Al-Tobasei R; Liu Q; Tansey WP; Weissmiller AM
BMC Genomics; 2024 Apr; 25(1):360. PubMed ID: 38605297
[TBL] [Abstract][Full Text] [Related]
6. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.
Imran A; Moyer BS; Canning AJ; Kalina D; Duncan TM; Moody KJ; Wolfe AJ; Cosgrove MS; Movileanu L
Biochem J; 2021 Jun; 478(11):2145-2161. PubMed ID: 34032265
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H
ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
[TBL] [Abstract][Full Text] [Related]
10. PARP1 interacts with WDR5 to enhance target gene recognition and facilitate tumorigenesis.
Qin Y; Dong X; Lu M; Jing L; Chen Q; Guan F; Xiang Z; Huang J; Yang C; He X; Qu J; Yang Z
Cancer Lett; 2024 Jul; 593():216952. PubMed ID: 38750719
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
[TBL] [Abstract][Full Text] [Related]
12. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F
Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
[TBL] [Abstract][Full Text] [Related]
14. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5.
Chen Y; Su H; Zhao J; Na Z; Jiang K; Bacchiocchi A; Loh KH; Halaban R; Wang Z; Cao X; Slavoff SA
Cell Rep; 2023 Sep; 42(9):113145. PubMed ID: 37725512
[TBL] [Abstract][Full Text] [Related]
15. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.
Wang F; Jeon KO; Salovich JM; Macdonald JD; Alvarado J; Gogliotti RD; Phan J; Olejniczak ET; Sun Q; Wang S; Camper D; Yuh JP; Shaw JG; Sai J; Rossanese OW; Tansey WP; Stauffer SR; Fesik SW
J Med Chem; 2018 Jul; 61(13):5623-5642. PubMed ID: 29889518
[TBL] [Abstract][Full Text] [Related]
17. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik SW; Liu Q; Tansey WP
bioRxiv; 2024 Jan; ():. PubMed ID: 37546802
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
19. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.
Thomas LR; Wang Q; Grieb BC; Phan J; Foshage AM; Sun Q; Olejniczak ET; Clark T; Dey S; Lorey S; Alicie B; Howard GC; Cawthon B; Ess KC; Eischen CM; Zhao Z; Fesik SW; Tansey WP
Mol Cell; 2015 May; 58(3):440-52. PubMed ID: 25818646
[TBL] [Abstract][Full Text] [Related]
20. Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5.
Cao J; Fan T; Li Y; Du Z; Chen L; Wang Y; Wang X; Shen J; Huang X; Xiong B; Cao D
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
